CSPC Pharmaceutical Group Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CSPC Pharmaceutical Group Limited
The past year witnessed only one major acquisition of a Chinese biotech by a major pharma company. However, some established firms such as Hansoh have set a new course for collaboration with much smaller peers by in-licensing preclinical assets.
The anti-Claudin-18.2 agent plus chemotherapy improves progression-free survival in inoperable or metastatic stomach cancer, following a similar Phase III readout in November.
As citizens in China grapple with the virtual end of pandemic restrictions and rush for medicines from cold remedies to traditional options, even some prescription antivirals such as Paxlovid are appearing online, while cheaper but unauthorized Indian generic versions have quickly sold out. Meanwhile, a renewed vaccination effort is targeting high-risk individuals and second booster shots as the country faces a huge surge in cases.
China's biopharma firms including Hengrui Medicine and HUTCHMED actively pursue licensing partners for their drug assets as the economic downturn caused by domestic COVID flare-ups continues worsening. Meanwhile, there are some predictions that smaller biotechs in the country may need to tap into multinationals' deep pockets to raise new funds.
- Medical Devices
- Research, Analytical Equipment & Supplies
- Generic Drugs
Drug Discovery Technologies
- Natural Products
- Molecular Diversity
- Large Molecule
- Other Names / Subsidiaries
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- NovaRock Biotherapeutics, Shijiazhuang Pharma Group
- China Shijiazhuang Pharmaceutical Group Co Ltd
- Hong Kong Tainuo Pharma Ltd
- Jiangsu Tainuo Pharmaceutical Co Ltd
- CSPC Pharmaceutical Group Co., Ltd.
- Shanghai Jinmante Biotechnology Co., Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.